Pandorum Technologies raises $18 M to increase global market access for programmable tissue regenerative therapies

image credit- freepik

Pandorum Technologies, a Bengaluru-based biotechnology company pioneering programmable regenerative medicine, with operations in India and the United States, has announced the closing of  a $18 million in Series B financing round, to advance the clinical development of its disease-modifying, tunable, exosome-based therapies, including Kuragenx, while scaling global manufacturing and expanding operations across the US, Japan, and the Middle East.

The round was led by Protons Corporate, with participation from Galentic Pharma, marquee investor Ashish Kacholia, Noblevast Advisory and Avinya Fund, Burman Family and others. Bandana Kankani, advisor and investor at Pandorum, had guided the transaction, optimizing the alignment between the investment architecture and company’s value creation.

Founded by Tuhin Bhowmick and Arun Chandru, Pandorum’s proprietary platform combines biology, engineering, and computation to develop tunable, regenerative exosome therapies that reprogram pathological tissue states, like inflammation and fibrosis, toward functional recovery.

Pandorum has implemented a globally distributed manufacturing strategy, including a CDMO partnership with AGC Biologics (Italy) for the US and European markets, and a strategic collaboration with Nucelion Therapeutics (India), a subsidiary of Bharat Biotech, to support supply across the Asia-Pacific region. The company is also exploring potential partnerships in the Middle East.

Pandorum’s primary focus is on ocular surface diseases, such as Stevens–Johnson Syndrome and Neurotrophic Keratitis, for which Kuragenx has received US FDA Orphan Drug Designation. In addition to ophthalmology, it is expanding its tunable platform to address systemic conditions, including inflammatory and degenerative diseases affecting the lung, liver, and nervous systems.